Beta-2- Glycoprotein -1 IgA, in Vasai Virar

A positive beta-2 glycoprotein (IgA) test indicates presence of an antiphospholipid antibody. It can be linked with antiphospholipid syndrome and increased risk of blood clots and pregnancy complications, though IgA findings are less standardized. Clinical correlation, repeat testing (including IgG/IgM and lupus anticoagulant), and specialist review are needed to assess risk and guide treatment.

Normal β2‑glycoprotein I antibody levels depend on the assay, but are generally reported as negative when below about 20 U/mL (or RU/mL). Values 20–40 U/mL are often considered borderline; >40 U/mL is typically positive. Reference ranges vary by laboratory and method, so use the lab’s interval and discuss abnormal results with a clinician; repeat testing at 12 weeks if positivity is suspected.

Beta‑2 glycoprotein I (β2GPI) is a circulating apolipoprotein that binds anionic phospholipids on cell membranes and apoptotic cells, aiding clearance and helping regulate coagulation. It modulates complement activity and platelet responses to maintain anticoagulant balance. Autoantibodies targeting β2GPI cause antiphospholipid syndrome, promoting thrombosis and pregnancy complications by disrupting these protective functions.

Yes. Beta‑2 glycoprotein I (β2‑GPI) is the main target of anti‑β2‑GPI antibodies, a type of antiphospholipid antibody linked to antiphospholipid syndrome (APS). APS often overlaps with systemic lupus erythematosus (SLE) and raises risks of blood clots and pregnancy loss. Detecting anti‑β2‑GPI antibodies helps diagnose APS in people with or without lupus and guide treatment.

A positive IgA test indicates the presence of Immunoglobulin A antibodies—evidence of a mucosal or systemic immune response. Depending on the test, it can reflect recent or ongoing infection, vaccination response, or autoimmune conditions (for example, IgA autoantibodies in celiac disease or IgA-associated kidney disease). Interpretation requires clinical context, complementary tests (IgG, IgM, titers) and discussion with a clinician.

A lupus anticoagulant test is a blood test that detects antiphospholipid antibodies associated with increased risk of blood clots and pregnancy loss. It screens using clotting assays (dRVVT and aPTT), followed by mixing and confirmatory tests that neutralize phospholipids. A positive result suggests antiphospholipid syndrome and is usually repeated after 12 weeks to confirm persistent antibodies.